Akari Therapeutics (AKTX) Competitors $0.88 -0.04 (-3.96%) Closing price 03:51 PM EasternExtended Trading$0.89 +0.01 (+0.56%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. CLYM, ALTS, ACOG, IKT, CGEN, SCLX, FATE, PLX, CHRS, and AVTXShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Climb Bio (CLYM), ALT5 Sigma (ALTS), Alpha Cognition (ACOG), Inhibikase Therapeutics (IKT), Compugen (CGEN), Scilex (SCLX), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Coherus Oncology (CHRS), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Climb Bio ALT5 Sigma Alpha Cognition Inhibikase Therapeutics Compugen Scilex Fate Therapeutics Protalix BioTherapeutics Coherus Oncology Avalo Therapeutics Akari Therapeutics (NASDAQ:AKTX) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership. Which has preferable earnings and valuation, AKTX or CLYM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$19.79MN/AN/AClimb BioN/AN/A-$73.90M-$0.70-3.54 Which has more risk & volatility, AKTX or CLYM? Akari Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Does the media prefer AKTX or CLYM? In the previous week, Climb Bio had 2 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for Climb Bio and 0 mentions for Akari Therapeutics. Climb Bio's average media sentiment score of 0.34 beat Akari Therapeutics' score of 0.00 indicating that Climb Bio is being referred to more favorably in the news media. Company Overall Sentiment Akari Therapeutics Neutral Climb Bio Neutral Do analysts recommend AKTX or CLYM? Akari Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 464.97%. Climb Bio has a consensus price target of $9.00, suggesting a potential upside of 262.90%. Given Akari Therapeutics' higher probable upside, analysts plainly believe Akari Therapeutics is more favorable than Climb Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Climb Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Do insiders & institutionals hold more shares of AKTX or CLYM? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 38.1% of Akari Therapeutics shares are owned by insiders. Comparatively, 0.8% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is AKTX or CLYM more profitable? Climb Bio's return on equity of -23.10% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A -78.03% -31.62% Climb Bio N/A -23.10%-22.47% SummaryClimb Bio beats Akari Therapeutics on 8 of the 12 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.65M$3.12B$5.82B$9.75BDividend YieldN/A2.24%4.40%4.08%P/E RatioN/A20.6430.1425.84Price / SalesN/A390.51469.15120.64Price / CashN/A43.2325.7828.79Price / Book1.059.649.425.99Net Income-$19.79M-$54.08M$3.27B$265.29M7 Day Performance-11.50%2.62%2.05%2.53%1 Month Performance-19.91%4.05%3.58%0.92%1 Year Performance-76.95%9.48%30.09%18.70% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics2.3038 of 5 stars$0.89-4.0%$5.00+465.0%-76.0%$29.65MN/A0.009CLYMClimb Bio3.3727 of 5 stars$2.11+11.1%$9.00+326.5%N/A$128.75MN/A-3.019Gap UpHigh Trading VolumeALTSALT5 Sigma0.4143 of 5 stars$6.12+3.0%N/A+158.7%$128.36M$12.53M0.00170Gap DownACOGAlpha Cognition2.3214 of 5 stars$8.44+5.5%$20.00+137.0%N/A$128.16MN/A-5.28N/AIKTInhibikase Therapeutics2.0928 of 5 stars$1.72-1.7%$6.50+277.9%+32.2%$127.87MN/A-0.646News CoverageCGENCompugen2.059 of 5 stars$1.55+8.4%$4.00+158.1%-28.9%$127.61M$27.86M-7.0570Positive NewsHigh Trading VolumeSCLXScilex2.388 of 5 stars$19.38+7.2%$455.00+2,247.8%-55.8%$125.76M$56.59M-0.6780FATEFate Therapeutics3.9398 of 5 stars$1.20+10.1%$3.58+198.6%-70.1%$125.71M$8.47M-0.83550Analyst RevisionPLXProtalix BioTherapeutics2.9684 of 5 stars$1.54+4.1%$15.00+874.0%+71.5%$122.60M$61.95M-11.85200CHRSCoherus Oncology4.1728 of 5 stars$1.07+1.9%$4.68+337.7%-11.5%$122.04M$266.96M0.69330News CoveragePositive NewsAVTXAvalo Therapeutics3.6678 of 5 stars$9.06+0.4%$30.00+231.1%+7.4%$118.63M$440K0.0040Positive News Related Companies and Tools Related Companies Climb Bio Competitors ALT5 Sigma Competitors Alpha Cognition Competitors Inhibikase Therapeutics Competitors Compugen Competitors Scilex Competitors Fate Therapeutics Competitors Protalix BioTherapeutics Competitors Coherus Oncology Competitors Avalo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access